Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
A Double-Blind, Placebo Controlled, Randomized Trial to Assess the Impact of a Monthly Administration of 50,000 IU of Vitamin D3 for 6 Months on Serum Levels of 25-Hydroxyvitamin D in Healthy Young Adults.

International journal of endocrinology

Brunel E, Schnitzler M, Foidart-Dessalle M, Souberbielle JC, Cavalier E.
PMID: 24324493
Int J Endocrinol. 2013;2013:652648. doi: 10.1155/2013/652648. Epub 2013 Nov 13.

In this double blind, unicentre, randomized, placebo controlled study, we evaluated the changes in 25-hydroxyvitamin D (25(OH)D) serum levels in 150 young Belgian adults (18-30 years), monthly supplemented with 50,000 IU of vitamin D (VTD) or placebo for 6...

Cite
Brunel E, Schnitzler M, Foidart-Dessalle M, et al. A Double-Blind, Placebo Controlled, Randomized Trial to Assess the Impact of a Monthly Administration of 50,000 IU of Vitamin D3 for 6 Months on Serum Levels of 25-Hydroxyvitamin D in Healthy Young Adults. Int J Endocrinol. 2013;2013:652648doi: 10.1155/2013/652648.
Brunel, E., Schnitzler, M., Foidart-Dessalle, M., Souberbielle, J. C., & Cavalier, E. (2013). A Double-Blind, Placebo Controlled, Randomized Trial to Assess the Impact of a Monthly Administration of 50,000 IU of Vitamin D3 for 6 Months on Serum Levels of 25-Hydroxyvitamin D in Healthy Young Adults. International journal of endocrinology, 2013652648. https://doi.org/10.1155/2013/652648
Brunel, E, et al. "A Double-Blind, Placebo Controlled, Randomized Trial to Assess the Impact of a Monthly Administration of 50,000 IU of Vitamin D3 for 6 Months on Serum Levels of 25-Hydroxyvitamin D in Healthy Young Adults." International journal of endocrinology vol. 2013 (2013): 652648. doi: https://doi.org/10.1155/2013/652648
Brunel E, Schnitzler M, Foidart-Dessalle M, Souberbielle JC, Cavalier E. A Double-Blind, Placebo Controlled, Randomized Trial to Assess the Impact of a Monthly Administration of 50,000 IU of Vitamin D3 for 6 Months on Serum Levels of 25-Hydroxyvitamin D in Healthy Young Adults. Int J Endocrinol. 2013;2013:652648. doi: 10.1155/2013/652648. Epub 2013 Nov 13. PMID: 24324493; PMCID: PMC3846150.
Copy Download .nbib Format: NLM
A Randomised, Double-Blinded, Placebo-Controlled, Parallel Study of Vitamin D3 Supplementation with Different Schemes Based on Multiples of 25,000 IU Doses.

International journal of endocrinology

Cavalier E, Faché W, Souberbielle JC.
PMID: 23431293
Int J Endocrinol. 2013;2013:327265. doi: 10.1155/2013/327265. Epub 2013 Jan 28.

Vitamin D (VTD) treatment is recommended in patients presenting different causes of diseases. To treat these patients, physicians rely on the different available pharmaceutical forms present in their country. Unfortunately, even in a given country, there is no consensus...

Cite
Cavalier E, Faché W, Souberbielle JC. A Randomised, Double-Blinded, Placebo-Controlled, Parallel Study of Vitamin D3 Supplementation with Different Schemes Based on Multiples of 25,000 IU Doses. Int J Endocrinol. 2013;2013:327265doi: 10.1155/2013/327265.
Cavalier, E., Faché, W., & Souberbielle, J. C. (2013). A Randomised, Double-Blinded, Placebo-Controlled, Parallel Study of Vitamin D3 Supplementation with Different Schemes Based on Multiples of 25,000 IU Doses. International journal of endocrinology, 2013327265. https://doi.org/10.1155/2013/327265
Cavalier, Etienne, et al. "A Randomised, Double-Blinded, Placebo-Controlled, Parallel Study of Vitamin D3 Supplementation with Different Schemes Based on Multiples of 25,000 IU Doses." International journal of endocrinology vol. 2013 (2013): 327265. doi: https://doi.org/10.1155/2013/327265
Cavalier E, Faché W, Souberbielle JC. A Randomised, Double-Blinded, Placebo-Controlled, Parallel Study of Vitamin D3 Supplementation with Different Schemes Based on Multiples of 25,000 IU Doses. Int J Endocrinol. 2013;2013:327265. doi: 10.1155/2013/327265. Epub 2013 Jan 28. PMID: 23431293; PMCID: PMC3568854.
Copy Download .nbib Format: NLM
Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation.

Frontiers in medicine

Roux A, Bendib Le Lan I, Holifanjaniaina S, Thomas KA, Picard C, Grenet D, De Miranda S, Douvry B, Beaumont-Azuar L, Sage E, Devaquet J, Cuquemelle E, Le Guen M, Suberbielle C, Gautreau C, Stern M, Rossetti M, Hamid AM, Parquin F.
PMID: 29075627
Front Med (Lausanne). 2017 Oct 11;4:155. doi: 10.3389/fmed.2017.00155. eCollection 2017.

Although donor-specific anti-human leukocyte antigen (HLA) antibodies (DSAs) are frequently found in recipients after lung transplantation (LT), the characteristics of DSA which influence antibody-mediated rejection (AMR) in LT are not fully defined. We retrospectively analyzed 206 consecutive LT patients...

Cite
Roux A, Bendib Le Lan I, Holifanjaniaina S, et al. Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation. Front Med (Lausanne). 2017;4:155doi: 10.3389/fmed.2017.00155.
Roux, A., Bendib Le Lan, I., Holifanjaniaina, S., Thomas, K. A., Picard, C., Grenet, D., De Miranda, S., Douvry, B., Beaumont-Azuar, L., Sage, E., Devaquet, J., Cuquemelle, E., Le Guen, M., Suberbielle, C., Gautreau, C., Stern, M., Rossetti, M., Hamid, A. M., & Parquin, F. (2017). Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation. Frontiers in medicine, 4155. https://doi.org/10.3389/fmed.2017.00155
Roux, Antoine, et al. "Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation." Frontiers in medicine vol. 4 (2017): 155. doi: https://doi.org/10.3389/fmed.2017.00155
Roux A, Bendib Le Lan I, Holifanjaniaina S, Thomas KA, Picard C, Grenet D, De Miranda S, Douvry B, Beaumont-Azuar L, Sage E, Devaquet J, Cuquemelle E, Le Guen M, Suberbielle C, Gautreau C, Stern M, Rossetti M, Hamid AM, Parquin F. Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation. Front Med (Lausanne). 2017 Oct 11;4:155. doi: 10.3389/fmed.2017.00155. eCollection 2017. PMID: 29075627; PMCID: PMC5641623.
Copy Download .nbib Format: NLM
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.

Therapeutic advances in neurological disorders

Pierrot-Deseilligny C, Rivaud-Péchoux S, Clerson P, de Paz R, Souberbielle JC.
PMID: 22783368
Ther Adv Neurol Disord. 2012 Jul;5(4):187-98. doi: 10.1177/1756285612447090.

BACKGROUND: Vitamin D could play a protective role in multiple sclerosis.METHODS: In an observational, uncontrolled study, vitamin D3 supplementation (3010 IU/day on average) was given to 156 consecutive patients with relapsing-remitting multiple sclerosis, under first-line immunomodulatory therapy and with...

Cite
Pierrot-Deseilligny C, Rivaud-Péchoux S, Clerson P, et al. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord. 2012;5(4):187-98doi: 10.1177/1756285612447090.
Pierrot-Deseilligny, C., Rivaud-Péchoux, S., Clerson, P., de Paz, R., & Souberbielle, J. C. (2012). Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Therapeutic advances in neurological disorders, 5(4), 187-98. https://doi.org/10.1177/1756285612447090
Pierrot-Deseilligny, Charles, et al. "Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation." Therapeutic advances in neurological disorders vol. 5,4 (2012): 187-98. doi: https://doi.org/10.1177/1756285612447090
Pierrot-Deseilligny C, Rivaud-Péchoux S, Clerson P, de Paz R, Souberbielle JC. Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation. Ther Adv Neurol Disord. 2012 Jul;5(4):187-98. doi: 10.1177/1756285612447090. PMID: 22783368; PMCID: PMC3388527.
Copy Download .nbib Format: NLM
Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays.

Endocrine connections

Sabbah N, Wolf P, Piedvache C, Trabado S, Verdelet T, Cornu C, Souberbielle JC, Chanson P.
PMID: 34343107
Endocr Connect. 2021 Aug 26;10(9):1027-1034. doi: 10.1530/EC-21-0175.

OBJECTIVE: Measurement of IGF-I is important in the management of patients with growth hormone disorders. Here we aim to establish normative data for two new IGF-I assay kits based on a large random sample of the French general adult...

Cite
Sabbah N, Wolf P, Piedvache C, et al. Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays. Endocr Connect. 2021;10(9):1027-1034doi: 10.1530/EC-21-0175.
Sabbah, N., Wolf, P., Piedvache, C., Trabado, S., Verdelet, T., Cornu, C., Souberbielle, J. C., & Chanson, P. (2021). Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays. Endocrine connections, 10(9), 1027-1034. https://doi.org/10.1530/EC-21-0175
Sabbah, Nadia, et al. "Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays." Endocrine connections vol. 10,9 (2021): 1027-1034. doi: https://doi.org/10.1530/EC-21-0175
Sabbah N, Wolf P, Piedvache C, Trabado S, Verdelet T, Cornu C, Souberbielle JC, Chanson P. Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays. Endocr Connect. 2021 Aug 26;10(9):1027-1034. doi: 10.1530/EC-21-0175. PMID: 34343107; PMCID: PMC8428081.
Copy Download .nbib Format: NLM
Face transplant: long-term follow-up and results of a prospective open study.

Lancet (London, England)

Lantieri L, Grimbert P, Ortonne N, Suberbielle C, Bories D, Gil-Vernet S, Lemogne C, Bellivier F, Lefaucheur JP, Schaffer N, Martin F, Meningaud JP, Wolkenstein P, Hivelin M.
PMID: 27567680
Lancet. 2016 Oct 01;388(10052):1398-1407. doi: 10.1016/S0140-6736(16)31138-2. Epub 2016 Aug 25.

BACKGROUND: More than 30 face transplantations have been done worldwide since 2005 but no documented long-term follow-up has been reported in the literature. We aimed to answer remaining question about the long-term risks and benefits of face transplant.METHODS: In...

Cite
Lantieri L, Grimbert P, Ortonne N, et al. Face transplant: long-term follow-up and results of a prospective open study. Lancet. 2016;388(10052):1398-1407doi: 10.1016/S0140-6736(16)31138-2.
Lantieri, L., Grimbert, P., Ortonne, N., Suberbielle, C., Bories, D., Gil-Vernet, S., Lemogne, C., Bellivier, F., Lefaucheur, J. P., Schaffer, N., Martin, F., Meningaud, J. P., Wolkenstein, P., & Hivelin, M. (2016). Face transplant: long-term follow-up and results of a prospective open study. Lancet (London, England), 388(10052), 1398-1407. https://doi.org/10.1016/S0140-6736(16)31138-2
Lantieri, Laurent, et al. "Face transplant: long-term follow-up and results of a prospective open study." Lancet (London, England) vol. 388,10052 (2016): 1398-1407. doi: https://doi.org/10.1016/S0140-6736(16)31138-2
Lantieri L, Grimbert P, Ortonne N, Suberbielle C, Bories D, Gil-Vernet S, Lemogne C, Bellivier F, Lefaucheur JP, Schaffer N, Martin F, Meningaud JP, Wolkenstein P, Hivelin M. Face transplant: long-term follow-up and results of a prospective open study. Lancet. 2016 Oct 01;388(10052):1398-1407. doi: 10.1016/S0140-6736(16)31138-2. Epub 2016 Aug 25. PMID: 27567680.
Copy Download .nbib Format: NLM
Factors influencing the growth hormone peak and plasma insulin-like growth factor I in young adults with pituitary stalk interruption syndrome.

BMC endocrine disorders

Marcu M, Trivin C, Souberbielle JC, Brauner R.
PMID: 18620575
BMC Endocr Disord. 2008 Jul 11;8:7. doi: 10.1186/1472-6823-8-7.

BACKGROUND: The diagnostic criteria for growth hormone (GH) deficiency (GHD) in adolescents and young adults are not yet clearly established.We evaluated the factors influencing the GH peak and plasma insulin-like growth factor (IGF) I in order to determine the...

Cite
Marcu M, Trivin C, Souberbielle JC, et al. Factors influencing the growth hormone peak and plasma insulin-like growth factor I in young adults with pituitary stalk interruption syndrome. BMC Endocr Disord. 2008;8:7doi: 10.1186/1472-6823-8-7.
Marcu, M., Trivin, C., Souberbielle, J. C., & Brauner, R. (2008). Factors influencing the growth hormone peak and plasma insulin-like growth factor I in young adults with pituitary stalk interruption syndrome. BMC endocrine disorders, 87. https://doi.org/10.1186/1472-6823-8-7
Marcu, Mariana, et al. "Factors influencing the growth hormone peak and plasma insulin-like growth factor I in young adults with pituitary stalk interruption syndrome." BMC endocrine disorders vol. 8 (2008): 7. doi: https://doi.org/10.1186/1472-6823-8-7
Marcu M, Trivin C, Souberbielle JC, Brauner R. Factors influencing the growth hormone peak and plasma insulin-like growth factor I in young adults with pituitary stalk interruption syndrome. BMC Endocr Disord. 2008 Jul 11;8:7. doi: 10.1186/1472-6823-8-7. PMID: 18620575; PMCID: PMC2474832.
Copy Download .nbib Format: NLM
Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Scientific reports

Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R.
PMID: 28300217
Sci Rep. 2017 Mar 16;7:44720. doi: 10.1038/srep44720.

No abstract available.

Cite
Hocine HR, Costa HE, Dam N, et al. Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Sci Rep. 2017;7:44720doi: 10.1038/srep44720.
Hocine, H. R., Costa, H. E., Dam, N., Giustiniani, J., Palacios, I., Loiseau, P., Bensussan, A., Borlado, L. R., Charron, D., Suberbielle, C., Jabrane-Ferrat, N., & Al-Daccak, R. (2017). Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Scientific reports, 744720. https://doi.org/10.1038/srep44720
Hocine, Hocine R, et al. "Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells." Scientific reports vol. 7 (2017): 44720. doi: https://doi.org/10.1038/srep44720
Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R. Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Sci Rep. 2017 Mar 16;7:44720. doi: 10.1038/srep44720. PMID: 28300217; PMCID: PMC5353623.
Copy Download .nbib Format: NLM
Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.

Therapeutic advances in neurological disorders

Pierrot-Deseilligny C, Souberbielle JC.
PMID: 23483715
Ther Adv Neurol Disord. 2013 Mar;6(2):81-116. doi: 10.1177/1756285612473513.

The contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis (MS) is reviewed. Among the multiple recently discovered actions of vitamin D, an immunomodulatory role has been documented in experimental autoimmune encephalomyelitis and in humans. This action...

Cite
Pierrot-Deseilligny C, Souberbielle JC. Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Ther Adv Neurol Disord. 2013;6(2):81-116doi: 10.1177/1756285612473513.
Pierrot-Deseilligny, C., & Souberbielle, J. C. (2013). Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Therapeutic advances in neurological disorders, 6(2), 81-116. https://doi.org/10.1177/1756285612473513
Pierrot-Deseilligny, Charles, and Souberbielle, Jean-Claude. "Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis." Therapeutic advances in neurological disorders vol. 6,2 (2013): 81-116. doi: https://doi.org/10.1177/1756285612473513
Pierrot-Deseilligny C, Souberbielle JC. Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis. Ther Adv Neurol Disord. 2013 Mar;6(2):81-116. doi: 10.1177/1756285612473513. PMID: 23483715; PMCID: PMC3582312.
Copy Download .nbib Format: NLM
Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Scientific reports

Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R.
PMID: 29052594
Sci Rep. 2017 Oct 20;7:46888. doi: 10.1038/srep46888.

This corrects the article DOI: 10.1038/srep41125.

Cite
Hocine HR, Costa HE, Dam N, et al. Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Sci Rep. 2017;7:46888doi: 10.1038/srep46888.
Hocine, H. R., Costa, H. E., Dam, N., Giustiniani, J., Palacios, I., Loiseau, P., Bensussan, A., Borlado, L. R., Charron, D., Suberbielle, C., Jabrane-Ferrat, N., & Al-Daccak, R. (2017). Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Scientific reports, 746888. https://doi.org/10.1038/srep46888
Hocine, Hocine R, et al. "Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells." Scientific reports vol. 7 (2017): 46888. doi: https://doi.org/10.1038/srep46888
Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R. Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells. Sci Rep. 2017 Oct 20;7:46888. doi: 10.1038/srep46888. PMID: 29052594; PMCID: PMC5649218.
Copy Download .nbib Format: NLM
Measurement of circulating 25-hydroxyvitamin D: A historical review.

Practical laboratory medicine

Le Goff C, Cavalier E, Souberbielle JC, González-Antuña A, Delvin E.
PMID: 28932799
Pract Lab Med. 2015 May 12;2:1-14. doi: 10.1016/j.plabm.2015.04.001. eCollection 2015 Aug 01.

The constantly increasing requests for the measurement of serum 25-hydroxyvitamin D over the last years has led reagent manufacturers to market different automated and semi-automated methods, that being unfortunately not fully harmonized, yield different results. Liquid chromatography coupled to...

Cite
Le Goff C, Cavalier E, Souberbielle JC, et al. Measurement of circulating 25-hydroxyvitamin D: A historical review. Pract Lab Med. 2015;2:1-14doi: 10.1016/j.plabm.2015.04.001.
Le Goff, C., Cavalier, E., Souberbielle, J. C., González-Antuña, A., & Delvin, E. (2015). Measurement of circulating 25-hydroxyvitamin D: A historical review. Practical laboratory medicine, 21-14. https://doi.org/10.1016/j.plabm.2015.04.001
Le Goff, C, et al. "Measurement of circulating 25-hydroxyvitamin D: A historical review." Practical laboratory medicine vol. 2 (2015): 1-14. doi: https://doi.org/10.1016/j.plabm.2015.04.001
Le Goff C, Cavalier E, Souberbielle JC, González-Antuña A, Delvin E. Measurement of circulating 25-hydroxyvitamin D: A historical review. Pract Lab Med. 2015 May 12;2:1-14. doi: 10.1016/j.plabm.2015.04.001. eCollection 2015 Aug 01. PMID: 28932799; PMCID: PMC5597717.
Copy Download .nbib Format: NLM
Vitamin D and its metabolites: from now and beyond.

EJIFCC

Cavalier E, Souberbielle JC.
PMID: 30050393
EJIFCC. 2018 Jul 11;29(2):105-110. eCollection 2018 Jul.

Total 25-hydroxyvitamin D is currently considered as the most representative metabolite of vitamin D status. There are a multitude of challenges that still deserve to be addressed and despite recent technological advances its determination remains complicated. This current review...

Cite
Cavalier E, Souberbielle JC. Vitamin D and its metabolites: from now and beyond. EJIFCC. 2018;29(2):105-110
Cavalier, E., & Souberbielle, J. C. (2018). Vitamin D and its metabolites: from now and beyond. EJIFCC, 29(2), 105-110.
Cavalier, Etienne, and Souberbielle, Jean-Claude. "Vitamin D and its metabolites: from now and beyond." EJIFCC vol. 29,2 (2018): 105-110.
Cavalier E, Souberbielle JC. Vitamin D and its metabolites: from now and beyond. EJIFCC. 2018 Jul 11;29(2):105-110. eCollection 2018 Jul. PMID: 30050393; PMCID: PMC6053816.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries